Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sofie Korn

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Lifetime Data Analysis|November 5, 2021
Bivariate pseudo-observations for recurrent event analysis with terminal eventsJulie K Furberg, Per K Andersen, Sofie Korn, et al.
The British Journal of Dermatology|January 27, 2022
The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trialMargitta Worm, Jacob P Thyssen, Sibylle Schliemann, et al.
Lancet (London, England)|July 21, 2024
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trialsRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Lifetime Data Analysis|November 5, 2021
Bivariate pseudo-observations for recurrent event analysis with terminal eventsJulie K Furberg, Per K Andersen, Sofie Korn, et al.
The British Journal of Dermatology|January 27, 2022
The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trialMargitta Worm, Jacob P Thyssen, Sibylle Schliemann, et al.
Lancet (London, England)|July 21, 2024
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trialsRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
Pageof 1